NanoBlade

NanoBlade is a biotechnology company based in Lyon, France, developing a transformative non-viral delivery platform for genome editing. Spun out from the ENS de Lyon, CNRS, and Inserm, the company leverages its proprietary NanoBlade technology, which utilizes engineered virus-like particles (VLPs) to deliver CRISPR-Cas9 ribonucleoproteins (RNPs) directly into target cells. This approach combines the high delivery efficiency of viral vectors with the safety profile of non-viral methods, as the particles do not integrate into the host genome and provide only transient expression of the editing machinery. NanoBlade focuses on enabling complex gene editing in hard-to-transfect primary cells, such as hematopoietic stem cells and T-cells, to address unmet needs in hematology and oncology. The company is currently in the pre-clinical stage, advancing its platform for both ex vivo cell therapy and potential in vivo applications.